avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
Published 5 years ago • 584 plays • Length 4:39Download video MP4
Download video MP3
Similar videos
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
3:22
biomarker analysis from javelin renal 101: avelumab plus axitinib versus sunitinib in arcc
-
4:48
prof jon haanan on the javelin study
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
0:44
real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
-
2:32
avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients
-
0:57
avelumab and axitinib for the treatment of advanced rcc
-
1:24
final results of avelumab and axitinib in rcc in the javelin renal 101 trial
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
0:47
avelumab plus axitinib shows good efficacy for os and pfs in arcc patients
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
1:06
dr. mcgregor on the utility of axitinib/avelumab in advanced rcc
-
1:37
immunotherapy combinations improve survival in advanced renal cell carcinoma
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
1:47
dr. choueiri discusses avelumab/axitinib data in rcc
-
9:23
javelin renal 101: avelumab plus axitinib improve pfs for advanced renal cell cancer